[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602166":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":29,"locations":37,"responsibleParty":229,"collaborators":11,"id":231,"slug":232,"hasResults":233,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":233,"sex":239,"minAge":240,"maxAge":11,"enrollmentInfo":241,"targetDuration":11,"studyType":244,"phases":245,"briefSummary":247,"conditions":248,"keywords":251,"overallStatus":142,"whyStopped":11,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":265},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Direct oral anticoagulants (DOACs)","EXPERIMENTAL",null,[13],"Biological: Additional blood sampling",{"label":15,"type":16,"description":11,"interventionNames":17},"Aspirin","ACTIVE_COMPARATOR",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"BIOLOGICAL","Additional blood sampling","At inclusion (T0) and at 12 months (T1), venous blood will be drawn for plasma markers of NETosis",[15,9],[25],{"name":26,"affiliation":27,"role":28},"Alexandre GUY","alexandre.guy@chu-bordeaux.fr","PRINCIPAL_INVESTIGATOR",[30,33],{"name":26,"role":31,"phone":32,"phoneExt":11,"email":27},"CONTACT","0557656478",{"name":34,"role":31,"phone":35,"phoneExt":11,"email":36},"Chloé JAMES","0557891979","chloe.james@chu-bordeaux.fr",[38,55,68,79,88,101,114,127,140,154,167,180,193,203,216],{"facility":39,"status":40,"city":41,"state":11,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"CHU d'Angers, Service des maladies du Sang","NOT_YET_RECRUITING","Angers","49933","France","FR",{"type":46,"coordinates":47},"Point",[48,49],-0.55202,47.47156,{"lat":49,"lon":48},[52],{"name":53,"role":31,"phone":11,"phoneExt":11,"email":54},"Corentin ORVAIN","corentin.orvain@chu-angers.fr",{"facility":56,"status":40,"city":57,"state":11,"zip":58,"country":43,"countryCode":44,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"CH de la Côte Basque, Service Hématologie","Bayonne","64100",{"type":46,"coordinates":60},[61,62],-1.473,43.49316,{"lat":62,"lon":61},[65],{"name":66,"role":31,"phone":11,"phoneExt":11,"email":67},"Frédéric BAUDUER","fbauduer@ch-cotebasque.fr",{"facility":69,"status":40,"city":70,"state":11,"zip":71,"country":43,"countryCode":44,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"CHU de Bordeaux, Service Hématologie Biologique","Bordeaux","33600",{"type":46,"coordinates":73},[74,75],-0.58046,44.84124,{"lat":75,"lon":74},[78],{"name":26,"role":31,"phone":11,"phoneExt":11,"email":27},{"facility":80,"status":40,"city":70,"state":11,"zip":71,"country":43,"countryCode":44,"cosmosGeoPoint":81,"geoPoint":83,"contacts":84},"CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire",{"type":46,"coordinates":82},[74,75],{"lat":75,"lon":74},[85],{"name":86,"role":31,"phone":11,"phoneExt":11,"email":87},"Clémence MEDIAVILLA","clemence.mediavilla@chu-bordeaux.fr",{"facility":89,"status":40,"city":90,"state":11,"zip":91,"country":43,"countryCode":44,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"CHU de Brest, Service Hématologie et Hémostase Clinique","Brest","29609",{"type":46,"coordinates":93},[94,95],-4.48628,48.39029,{"lat":95,"lon":94},[98],{"name":99,"role":31,"phone":11,"phoneExt":11,"email":100},"Jean-Christophe IANOTTO","jean-christophe.ianotto@chu-brest.fr",{"facility":102,"status":40,"city":103,"state":11,"zip":104,"country":43,"countryCode":44,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"APHP-Hôpital Mondor, Service Hématologie Clinique et Thérapie Cellulaire","Créteil","94010",{"type":46,"coordinates":106},[107,108],2.46569,48.79266,{"lat":108,"lon":107},[111],{"name":112,"role":31,"phone":11,"phoneExt":11,"email":113},"Lydia ROY","lydia.roy@aphp.fr",{"facility":115,"status":40,"city":116,"state":11,"zip":117,"country":43,"countryCode":44,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"CHD de Vendée, Service Onco-hématologie","La Roche-sur-Yon","85925",{"type":46,"coordinates":119},[120,121],-1.42757,46.66974,{"lat":121,"lon":120},[124],{"name":125,"role":31,"phone":11,"phoneExt":11,"email":126},"Bruno VILLEMAGNE","bruno.villemagne@ght85.fr",{"facility":128,"status":40,"city":129,"state":11,"zip":130,"country":43,"countryCode":44,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"APHP-Hôpital Bicêtre, Service Hématologie Clinique Ambulatoire","Le Kremlin-Bicêtre","94270",{"type":46,"coordinates":132},[133,134],2.36073,48.81471,{"lat":134,"lon":133},[137],{"name":138,"role":31,"phone":11,"phoneExt":11,"email":139},"Laurence LEGROS","laurence.legros@aphp.fr",{"facility":141,"status":142,"city":143,"state":11,"zip":144,"country":43,"countryCode":44,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"CH de Libourne, Service Hématologie","RECRUITING","Libourne","33505",{"type":46,"coordinates":146},[147,148],-0.24186,44.91449,{"lat":148,"lon":147},[151],{"name":152,"role":31,"phone":11,"phoneExt":11,"email":153},"Diane LARA","diane.lara@ch-libourne.fr",{"facility":155,"status":40,"city":156,"state":11,"zip":157,"country":43,"countryCode":44,"cosmosGeoPoint":158,"geoPoint":162,"contacts":163},"CHU de Limoges, Service Hématologie Clinique et de Thérapie Cellulaire","Limoges","87042",{"type":46,"coordinates":159},[160,161],1.24759,45.83362,{"lat":161,"lon":160},[164],{"name":165,"role":31,"phone":11,"phoneExt":11,"email":166},"Amélie PENOT","amelie.penot@chu-limoges.fr",{"facility":168,"status":40,"city":169,"state":11,"zip":170,"country":43,"countryCode":44,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"CH des Pays de Morlaix, Service Onco-Hématologie","Morlaix","29672",{"type":46,"coordinates":172},[173,174],-3.82792,48.57784,{"lat":174,"lon":173},[177],{"name":178,"role":31,"phone":11,"phoneExt":11,"email":179},"Christophe NICOL","cnicol@ch-morlaix.fr",{"facility":181,"status":40,"city":182,"state":11,"zip":183,"country":43,"countryCode":44,"cosmosGeoPoint":184,"geoPoint":188,"contacts":189},"CHU de Nantes, Service Hématologie Clinique","Nantes","44093",{"type":46,"coordinates":185},[186,187],-1.55336,47.21725,{"lat":187,"lon":186},[190],{"name":191,"role":31,"phone":11,"phoneExt":11,"email":192},"Viviane DUBRUILLE","viviane.dubruille@chu-nantes.fr",{"facility":194,"status":40,"city":182,"state":11,"zip":195,"country":43,"countryCode":44,"cosmosGeoPoint":196,"geoPoint":198,"contacts":199},"Hôpital Privé du Confluent, Service Hématologie","44202",{"type":46,"coordinates":197},[186,187],{"lat":187,"lon":186},[200],{"name":201,"role":31,"phone":11,"phoneExt":11,"email":202},"Katell LE DU","dr.ledu@groupeconfluent.fr",{"facility":204,"status":40,"city":205,"state":11,"zip":206,"country":43,"countryCode":44,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"APHO-Hôpital Saint-Louis, Centre d'Investigations Cliniques","Paris","75010",{"type":46,"coordinates":208},[209,210],2.3488,48.85341,{"lat":210,"lon":209},[213],{"name":214,"role":31,"phone":11,"phoneExt":11,"email":215},"Juliette SORET-DULPHY","juliette.soret@aphp.fr",{"facility":217,"status":40,"city":218,"state":11,"zip":219,"country":43,"countryCode":44,"cosmosGeoPoint":220,"geoPoint":224,"contacts":225},"CH de Roubaix, Service Hématologie","Roubaix","59100",{"type":46,"coordinates":221},[222,223],3.17456,50.69421,{"lat":223,"lon":222},[226],{"name":227,"role":31,"phone":11,"phoneExt":11,"email":228},"Mathieu WEMEAU","mathieu.wemeau@ch-roubaix.fr",{"type":230,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100602166","prognostic-value-of-netosis-markers-for-thrombosis-during-myeloproliferative-neoplasms-avatare-100602166",false,"NCT07119970","Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)","Prospective Study for the Evaluation of the Prognostic Value of NETosis Markers to Predict Thrombosis in Myeloproliferative Neoplasms With JAK2V617F Mutation (AVATARE)","AVATARE","Inclusion Criteria:\n\n* Diagnosis of Polycythemia Vera (PV), Essential Thrombocythemia (ET), or pre-myelofibrosis (pre-MF)\n* JAK2V617F mutation with an allelic burden greater than 1%\n* High risk of thrombosis (age over 60 years or prior thrombotic event)\n* Diagnosis of MPN within the last 12 months\n* Enrollment in the AVAJAK clinical trial and the FIMBANK biobank\n* Affiliation with social security\n* Signed informed consent\n\nExclusion Criteria:\n\n* Severe hepatic or renal insufficiency (Creatinine clearance \\\u003C30ml\u002Fmin)\n* Patients under legal protection (guardianship or curatorship)\n* Patients under heparin treatment at inclusion","ALL","18 Years",{"count":242,"type":243},300,"ESTIMATED","INTERVENTIONAL",[246],"NA","Myeloproliferative neoplasms are hematologic diseases characterized by an increased proliferation of peripheral blood cells. The main risk of MPN is the occurrence of thrombosis. Thrombosis risk is mainly evaluated using two criteria: age and prior thrombosis. A better prediction of thrombosis risk is needed to improve prevention and treatment of MPN-associated thrombosis. The objective of the study is to evaluate the predictive value of neutrophil extracellular traps markers in thrombosis during MPN.",[249,250],"Myeloproliferative Neoplasm","Myeloproliferative Disorders",[252,253,254,255],"Myeloproliferative neoplasms","Thrombosis","Neutrophil extracellular traps","Neutrophils","2026-01-09",{"date":258,"type":259},"2026-01-13","ACTUAL",{"date":261,"type":259},"2025-12-09",{"date":263,"type":243},"2030-12",{"name":5,"class":6},15]